Blinded independent central review of the progression-free survival endpoint.
Amit
Ohad
O
GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Bushnell
Will
W
Dodd
Lori
L
Roach
Nancy
N
Sargent
Daniel
D
D017326:Clinical Trials, Phase III as Topic / Q000592:standards*; D003625:Data Collection; D018572:Disease-Free Survival; D004311:Double-Blind Method; D023381:Endpoint Determination; D006801:Humans; D008485:Medical Audit / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D016896:Treatment Outcome